US Broker Ratings

Iovance Biotherapeutics, Inc. (IOVA) Stock Analysis: A High-Risk Bet with 153% Upside Potential

Investors with a penchant for high-risk, high-reward opportunities may find Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) an intriguing prospect. The biopharmaceutical company, with a market capitalization of $1.59 billion, is a..

iRadimed Corporation (IRMD) Stock Analysis: Unpacking a 36.81% Potential Upside with Strong Buy Ratings

Investors looking for compelling opportunities in the healthcare sector should turn their attention to iRadimed Corporation (NASDAQ: IRMD), a leading developer and manufacturer of MRI-compatible medical devices. With a market..

GH Research PLC (GHRS) Stock Analysis: Biotech Innovator with 86.82% Potential Upside

GH Research PLC (NASDAQ: GHRS), a promising player in the biopharmaceutical sector, is garnering significant investor attention due to its innovative approach to treating mental health disorders. Based in Dublin,..

Amylyx Pharmaceuticals, Inc. (AMLX) Stock Analysis: Exploring a Potential 53% Upside with Strong Buy Ratings

Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) stands as a compelling investment opportunity in the healthcare sector, particularly within the specialty and generic drug manufacturing industry. Headquartered in Cambridge, Massachusetts, this clinical-stage..

KalVista Pharmaceuticals, Inc. (KALV) Stock Analysis: Unpacking Growth Potential Amidst Analyst Optimism

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a beacon in the biotechnology sector, is drawing significant attention from investors due to its ambitious pipeline and promising market positioning. With a market capitalization..

Upstream Bio, Inc. (UPB) Stock Analysis: A Promising 384.94% Potential Upside in the Biotech Sector

Upstream Bio, Inc. (NASDAQ: UPB) is gaining attention in the investment community with its remarkable potential upside of 384.94%, according to recent analyst ratings. As a clinical-stage biotechnology company, Upstream..

Vir Biotechnology, Inc. (VIR) Stock Analysis: Unveiling a Potential 124% Upside for Investors

Vir Biotechnology, Inc. (VIR) stands at a pivotal moment in its growth trajectory, presenting a remarkable investment opportunity for those interested in the healthcare sector, particularly within biotechnology. Headquartered in..

CeriBell, Inc. (CBLL) Stock Analysis: A Promising 35% Upside in the Medical Devices Sector

CeriBell, Inc. (NASDAQ: CBLL), a rising star in the healthcare sector, is capturing the attention of investors with its innovative medical device solutions and a substantial potential upside of 35.29%...

Bicycle Therapeutics plc (BCYC) Stock Analysis: Revealing a Potential 147.67% Upside

Bicycle Therapeutics plc (NASDAQ: BCYC), a pioneering biotechnology firm headquartered in Cambridge, UK, is drawing significant attention from the investment community. Operating within the healthcare sector, the company is focused..

Evolus, Inc. (EOLS): Analyzing a 129% Potential Upside with a Strong Analyst Consensus

Evolus, Inc. (NASDAQ: EOLS), a dynamic player in the healthcare sector, is capturing investor interest with a compelling narrative of growth potential. Specializing in the performance beauty market, Evolus focuses..

Immunome, Inc. (IMNM) Stock Analysis: Exploring a 60% Potential Upside in the Biotech Sector

Immunome, Inc. (NASDAQ: IMNM) stands out in the biotechnology sector with its bold strides in oncology therapeutics, particularly in antibody-drug conjugates. Despite a 0.05% dip in its current price to..

Delcath Systems, Inc. (DCTH) Stock Analysis: Aiming for an 89.80% Upside in the Medical Device Sector

Delcath Systems, Inc. (NASDAQ: DCTH) is catching the eye of investors with its significant potential upside of 89.80%, as reflected in recent analyst ratings. With a current market cap of..

Relay Therapeutics, Inc. (RLAY) Stock Analysis: Exploring a 67.87% Potential Upside

Relay Therapeutics, Inc. (NASDAQ: RLAY) stands out in the biotechnology sector with promising growth potential, despite the challenges highlighted by its recent financial performance. As a clinical-stage precision medicines company,..

Talkspace, Inc. (TALK) Stock Analysis: Exploring the 18.73% Potential Upside for Investors

Talkspace, Inc. (TALK), a leader in virtual behavioral healthcare, is gaining attention from investors as it positions itself within the rapidly growing telehealth sector. With a market capitalization of $867.72..

Eton Pharmaceuticals, Inc. (ETON) Stock Analysis: Navigating a 32% Potential Upside in the Rare Disease Market

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) is steadily capturing the attention of investors with its focused approach in the healthcare sector, specifically targeting the niche market of treatments for rare diseases...

Valneva SE (VALN) Stock Analysis: Exploring a Potential 119.87% Upside in the Biotechnology Sector

Valneva SE (NASDAQ: VALN), a French biotechnology company specializing in the development of vaccines for infectious diseases, presents a compelling opportunity for investors with its robust product pipeline. Despite recent..

Geron Corporation (GERN) Stock Analysis: Exploring a 173.97% Potential Upside in Innovative Cancer Therapies

Geron Corporation (NASDAQ: GERN) is capturing investor attention with its promising potential upside of 173.97%, as highlighted by recent analyst ratings. This commercial-stage biopharmaceutical company, headquartered in Foster City, California,..

Keros Therapeutics, Inc. (KROS) Stock Analysis: Unveiling a 93.91% Potential Upside for Investors

Keros Therapeutics, Inc. (NASDAQ: KROS), a clinical-stage biopharmaceutical company, is drawing significant attention from investors with an impressive potential upside of 93.91%, according to recent analyst ratings. Headquartered in Lexington,..

InMode Ltd. (INMD) Stock Analysis: Exploring the 16.74% Potential Upside in the Medical Devices Sector

Investors with a keen interest in the healthcare sector, particularly in medical devices, may find InMode Ltd. (NASDAQ: INMD) an intriguing prospect. Headquartered in Yokne’am, Israel, InMode is a key..

Sionna Therapeutics, Inc. (SION): Investor Outlook on its Promising 16.83% Upside Potential

Sionna Therapeutics, Inc. (SION), a clinical-stage biopharmaceutical company, is capturing investor attention with its ambitious pipeline focused on treating cystic fibrosis (CF). As a trailblazer in the biotechnology industry, Sionna..

Search

Funds

US Broker Ratings

Search

Funds

US Broker Ratings

FTSE 100

Funds